How GLP-1 Policy Fits Into Trump’s Greenland Strategy, And 5 Other Health Tech Developments

The U.S. government’s healthcare policy decisions could have significant economic and geopolitical implications, particularly concerning Denmark’s largest company, Novo Nordisk. With its market capitalization nearing Denmark’s GDP, Novo Nordisk plays a crucial role in the country’s economy. Former President Trump’s interest in acquiring Greenland raised speculation about potential economic pressure tactics, including regulatory shifts affecting Denmark’s pharmaceutical sector.Meanwhile, the FDA recently removed semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) from its drug shortage list, ensuring broader access to GLP-1 drugs. Originally developed for diabetes, these medications are now widely used for weight loss, with 30 million Americans having taken them. Regulatory changes and supply chain developments continue to shape the future of these influential treatments.